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Abstract:
Background: Chronic hyperglycemia in type 2 diabetes
increases the risk of microvascular events. However, there
is continuing uncertainty about its effect on macrovas-
cular outcomes and death. We conducted a meta-analysis
of prospective studies to estimate the association of
glycosylated hemoglobin level with the risk of all-cause
mortality and cardiovascular outcomes among patients
with type 2 diabetes.
Methodology/Principal Findings: We systematically
searched the MEDLINE database through April 2011 by
using Medical Subject Heading search terms and a
standardized protocol. We included prospective cohort
studies that reported data of glycosylated hemoglobin
level on the risk of incident cardiovascular events and all-
cause mortality. Relative risk estimates (continuous and
categorical variables) were derived or abstracted from
each cohort study. Twenty six studies were included in
this analysis with a mean follow-up rang of 2.2–16 years.
The pooled relative risk associated with a 1% increase in
glycosylated hemoglobin level among patients with type
2 diabetes was 1.15 (95% CI, 1.11 to 1.20) for all-cause
mortality, 1.17 (95% CI, 1.12 to 1.23) for cardiovascular
disease, 1.15 (95% CI, 1.10 to 1.20) for coronary heart
disease, 1.11 (95% CI, 1.05 to 1.18) for heart failure, 1.11
(95% CI, 1.06 to 1.17) for stroke, and 1.29 (95% CI, 1.18 to
1.40) for peripheral arterial disease, respectively. In
addition, a positive dose-response trend existed be-
tween glycosylated hemoglobin level and cardiovascular
outcomes.
Conclusions/Significance: Chronic hyperglycemia is asso-
ciated with an increased risk for cardiovascular outcomes
and all-cause mortality among patients with type 2
diabetes, likely independently from other conventional
risk factors.
Introduction
Type 2 diabetes continues to be one of the most common and
important public health crises worldwide. It has been estimated
that the global health expenditure on diabetes is at least $376
billion in 2010 and will be $490 billion in 2030 [1]. Type 2
diabetes is a major risk factor for cardiovascular disease (CVD).
Patients with type 2 diabetes have a 2–4 times higher risk of CVD
mortality than those without diabetes [2,3]. CVD accounts for
approximately 70% of death among patients with type 2 diabetes
[4,5].
The key risk factor associated with diabetes complications is
poor glycemic control [6]. Growing evidence has linked chronic
hyperglycemia to microvascular complications [7–9]. Although
improving glycemic control has been demonstrated to reduce
microvascular complications in patients with type 2 diabetes
[9,10], the relationship between glycosylated hemoglobin (GHb)
level and macrovascular complications and all-cause mortality is
still uncertain. In three meta-analyses [11–13] of published
randomized controlled trials (RCTs), intensive glycemic control
showed positive effects on some cardiovascular outcomes, but did
not reduce the risk of death from CVD and all causes. However,
these studies were constrained by inherent limitations of the
clinical trials, which might have been underpowered to show
clinical benefits - especially if event rates were lower than expected
or the studies had a high lost follow-up rate [14].
A meta-analysis of 10 prospective studies evaluating the
association of GHb level with CVD risk among patients with
type 2 diabetes has found that every 1% increase in GHb was
associated with an 18% increase in the risk of CVD events [15].
However, this meta-analysis did not estimate the association of
GHb level with the risk of all-cause mortality. Moreover, among
all prospective studies included, only two studies had a baseline
sample size greater than 2,000 [16,17]. In recent years, several
high quality and large prospective studies have assessed the
association of GHb level with the risks of CVD outcomes and/or
all-cause mortality in patients with type 2 diabetes, but the results
are inconsistent. With respect to all-cause mortality, a U-shape
association [18] and a non-linear positive association [19] have
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been reported in these cohort studies. For CVD outcomes, most
studies reported a positive association [19–24], whereas one study
found no relation [25]. In addition, some data from previous
cohort studies have been updated recently [17,26,27].
To clarify whether lowering long-term GHb level can reduce
the risks for CVD outcomes and all-cause mortality, we performed
a systematic review and meta-analysis with the most updated
prospective data to evaluate the association of GHb level with the
risks of incident CVD outcomes and all-cause mortality in patients
with type 2 diabetes.
Methods
Data Sources and Searches
We searched the MEDLINE database for articles published in
English from January 1974 to April 2011 by using Medical Subject
Heading (MeSH) terms cardiovascular diseases; coronary heart disease;
heart failure; stroke; peripheral arterial disease; all-cause mortality; and
diabetes mellitus, type 2, as well as glycemic control, and glycosylated
hemoglobin or HbA1c. We also performed a manual searching of
references cited by original studies and relevant review articles and
queried experts to identify any additional studies. This search
provided 3123 articles, which were further screened for inclusion
from abstracts or full texts.
Study Selection
We selected the studies based on the following conditions: 1)
study design: prospective cohort studies; 2) study population:
patients with type 2 diabetes; 3) studies reported at least one of the
outcomes of interest: cardiovascular outcomes (CVD, CVD
mortality, coronary heart disease (CHD), fatal CHD, heart failure,
and stroke), peripheral arterial disease (PAD), and all-cause
mortality; and 4) studies reported a measure of GHb (HbA1C,
HbA1, and total GHb). We first identified 55 full-text articles and
then excluded some if they 1) had no original data (review,
editorials, meta-analyses), 2) involved non prospective analysis
(e.g., nest case–control studies), 3) had follow-up time ,1 year, 4)
included patients with type 2 diabetes receiving dialysis, or with
heart failure, or with disability, or 5) were duplicate publications. If
separate articles from the same study were published, the article
with the most updated data was selected for use in this study. In
the case of duplicate publications, only one publication was
included.
Data Extraction and Quality Assessment
Data were extracted by two independent reviewers (ZY and
GH) using standardized data abstraction forms. Disagreements
between reviewers were resolved by repeated examination of the
original articles and discussion until consensus was achieved.
Information on surname of the first author, year of publication,
country of origin, mean age, percentage of male of study
participants, sample size, number of study participants included
in the final analysis, duration of follow-up, outcomes, estimate of
the risk of association, variables adjusted in the analyses was
extracted. For assessment of study quality, we evaluate 6 major
items of each study: 1) is the instrument for measuring GHb
validated? 2) does GHb allow quantification as both continuous
and categorized variables? 3) are the outcomes determined by the
specified criteria (i.e., medical record) or physician’s or patient’s
judgments such as registry, death certificate, questionnaire, and
patients’ self-report? 4) is the total follow-up duration $5 years? 5)
are major CVD risk factors for in the statistical analyses, such as
age, sex, blood pressure (hypertension), dyslipidemia (or LDL/
total cholesterol level), smoking, duration of diabetes, treatment,
albuminuria, etc? and 6) are subjects lost-to-follow up excluded
from the analysis?
During data extraction, we abstracted adjusted relative risk
(RR) for the association between GHb level either as a continuous
or a categorical variable and the major outcomes (see below).
Standard errors (SEs) for the estimates were abstracted or derived
by using data reported in the original studies. When necessary, the
original authors were contacted for additional information (3
authors contacted and 2 responded).
Reviewers recorded the following as the major outcomes of
interest: all-cause mortality, incident CVD (non-fatal myocardial
infarction, non-fatal stoke, and fatal CVD), CVD mortality,
incident CHD (non-fatal myocardial infarction, and fatal CHD),
CHD mortality, heart failure (non-fatal and fatal heart failure),
incident stroke (non-fatal and fatal stoke), and PAD (lower-
extremity peripheral arterial disease, amputation, and claudica-
tion).
Data Synthesis and Analysis
Separate meta-analyses of the prospective cohort studies were
carried out for the above major outcomes. All RRs estimates
included in the pooled analyses were from the most fully adjusted
multivariable models.
Most of the studies included in the present analysis reported the
RRs of per unit change of GHb level, therefore, we converted
studies that used different units in their original analyses based on
the method previously published [15]. For example, there were 3
studies [28–30] that compared the RR for participants in the 3rd
tertile of GHb to participants in the 2 lowest tertiles. In order to
make these results comparable to the rest of studies, we assumed
that there was a normal distribution for GHb values and used the
reported mean and standard deviation (SD) to estimate the 33rd
and 83rd percentiles of GHb (corresponding to the midpoints of
the 2 lowest and the highest tertiles, respectively). Then, we
divided the log RRs by the difference of these 2 values to estimate
the effect of a 1% change in HbA1 [31]. Similarly, for one study
[32] that compared the reported RR of above and below the
median value of GHb, we estimated the effect of a 1% change but
calculated the 25th and 75th percentiles instead.
After the RR estimate from each cohort study was converted to
reflect a 1% increase in GHb [31], the pooled RRs and 95%
confidence intervals (CIs) were calculated using the random-effects
model. Statistical heterogeneity was assessed using the DerSimo-
nian and Laird’s Q statistic and I2 statistic. The Q test provides
information about the presence or absence of between-study
heterogeneity, whereas the I2 statistic quantifies the degree of
heterogeneity and is interpretable as the percentage of the total
association that may be due to heterogeneity between studies
(I2.50% was considered a meaningful level of heterogeneity). We
also conducted a sensitivity analysis in which each prospective
cohort study was excluded in turn to evaluate the influence of that
prospective cohort study on the overall estimate. Publication bias
was examined using funnel plots and Begg’s test. A meta-
regression analysis was conduced to explore the sources of
statistical heterogeneity in the meta-analyses. Subgroup analyses
were conducted by stratifying the analysis according to studies that
in different areas. All analyses were conducted by using STATA
10.0 (Stata Corporation, College Station, TX).
Results
Of 3123 articles that were identified from the literature search,
3068 were excluded after an abstract or full-text review (Figureoˆ 1).
Of the 55 articles for further review, 43 articles were relevant to
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Figure 1. Flow diagram of studies assessed and included.
doi:10.1371/journal.pone.0042551.g001
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GHb, macrovascular outcomes and all-cause mortality. Of these
43 articles, we excluded two that were not conducted in patients
with type 2 diabetes [33,34], two with follow-up time less than 1
year [35,36], seven that were duplicated reports [5,26,37–41], one
that had type 2 diabetes patients with heart failure at baseline [42],
one with hemodialysis [43], and one with disable older women
[44]. In addition, we excluded two nest case-control studies
because of we were unable to perform the pooled analysis with
other studies [45,46]. Finally, 27 articles [16–25,27–30,32,47–58]
that reported 26 independent prospective cohorts were included in
the present meta-analysis. Of them, two articles reported the same
outcome with the same cohort study but using different analyses:
one used continuous variable [56] and the other used categorical
variable [22].
Table 1 summarizes the characteristics of the studies included in
the present analysis. The sample size ranged from 94 to 48,858
Figure 2. Forest plot of relative risks (RRs) and 95% confidence intervals (CIs) for the association between glycosylated hemoglobin
and the main study outcomes risks in type 2 diabetes. CVD: cadiovascular diseases; CHD: conoary heart disease; PAD: peripheral arterial
disease.
doi:10.1371/journal.pone.0042551.g002
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participants, 10 studies (38%) had more than 3,000 patients of type
2 diabetes, and 3 studies [18,21,24] (12%) had more than 45,000.
The mean follow-up time ranged from 2.2 to 16 years. The studies
included were geographically heterogeneous: 5 were conducted in
the United States (US), 7 in United Kingdom (UK), 4 in Finland, 2
in The Netherlands, 1 in Sweden, 1 in Denmark, 1 in Italy, 1 in
Germany, 2 in New Zealand, and 2 in China. Most studies had
primary care or clinic-based patient populations. Both men and
women were included in 25 of the 26 studies; the remaining study
included only men [51].
Most studies modeled the effect of baseline GHb measurements
on the risk for incident CVD outcomes; however, 2 studies [47,50]
used updated mean GHb levels and modeled GHb as a time-
dependent variable in the multivariable models.
The quality assessments of the included studies were summa-
rized in the Supplementary tableoˆ 1. The overall quality of
included studies was good according to our 6-item evaluation
criteria. All the studies adjusted for major CVD risk factors in the
statistical analyses, had validated instrument for measuring GHb,
had outcomes determined by specified criteria, and excluded
participants who were lose during the follow-up (table S1). All
studies had follow-up time longer than 1 year and only 4 studies
had follow-up less than 5 years [18,21,24,32]. Most studies treated
GHb as continuous variables, and 5 studies treated GHb both as
continuous and categorized variables in the analyses
[19,20,21,24,49].
Figureoˆ 2 presents the individual and pooled RRs for all-cause
mortality and cardiovascular outcomes. The pooled RR associated
with a 1% increase in GHb level among patients with type 2
diabetes was 1.15 (95% CI, 1.11 to 1.20) for all-cause mortality in
7 independent studies, 1.17 (95% CI, 1.12 to 1.23) for incident
CVD in 14 independent studies, 1.25 (95% CI, 1.15 to 1.35) for
CVD mortality in 10 independent studies, 1.15 (95% CI, 1.10 to
1.20) for incident CHD in 8 independent studies, 1.17 (95% CI,
1.10 to 1.26) for fatal CHD in 5 independent studies, 1.11 (95%
CI, 1.05 to 1.18) for incident heart failure in 3 independent studies,
1.11 (95% CI, 1.06 to 1.17) for incident stroke in 4 independent
studies, and 1.29 (95% CI, 1.18 to 1.40) for incident PAD in 3
independent studies, respectively. The funnel plots and Begg’s test
(figure S1) suggested that potential publication bias might be
present for the CVD (P= 0.01) and CVD mortality (P = 0.004),
but not for all-cause mortality (P = 0.07), CHD (P= 0.11), fatal
CHD (P= 0.09), heart failure (P = 0.3), stroke (P = 0.09), and PAD
(P= 0.2). In sensitivity analyses, exclusion of any single prospective
cohort study from the analysis did not alter the overall findings of a
positive association between GHb level and cardiovascular
outcomes, and association between GHb level and all-cause
mortality.
We also analyzed the heterogeneity among the studies of
cardiovascular outcomes and all-cause mortality in persons with
type 2 diabetes. The I2 statistics (P values for the Q test) in the
above analyses were 21.8% (0.26) for all-cause mortality, 65.2%
(,0.001) for CVD, 43.8% (0.07) for CVD mortality, 25.1% (0.23)
for CHD, 16.6% (0.31) for fatal CHD, 33.9% (0.22) for heart
failure, 0.0% (0.79) for stroke, and 0.0% (0.70) for PAD,
respectively, which indicated no statistically significant heteroge-
neity for these pooled results except incident CVD.
To further investigate the potential sources of heterogeneity, we
conducted subgroup analyses that compared the relative risk
estimates for studies that adjusted for age, sex, blood pressure, and
lipids with those that did not: for CVD, the pooled RR was 1.19
(95% CI, 1.11 to 1.27) for 9 studies adjusted for BP and lipids and
1.16 (95% CI, 1.05 to 1.29) for 5 studies that did not adjust for BP
and lipids; for CHD, it was 1.17 (95% CI, 1.11 to 1.24; 5 studies
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adjusted for BP and lipids) vs.1.12 (95% CI, 1.03 to 1.21; 3 studies
did not adjust for BP and lipids); for fatal CHD, it was 1.24 (95%
CI, 1.06 to 1.46; 3 studies adjusted for BP and lipids) vs. 1.15 (95%
CI, 1.08 to 1.21; 3 studies did not adjust for BP and lipids). In
addition, we also conducted meta-regression and subgroup
analyses to compare the RRs for studies that were conducted in
different areas. For 6 outcomes (e.g. all-cause mortality, CVD,
CVD mortality, CHD, fatal CHD, stroke) that allowed us to
conduct meta-regression, area was not a significant factor that
contributed to the heterogeneity (all P values .0.05).
Tableoˆ 2 shows the individual RRs for cardiovascular outcomes
according to categories of GHb levels. Eight studies reporting $3
categories of the GHb level were included. Among them, only 1
study reported both the case number and the total number of each
category subgroup, thus we could not carry out the dose-response
meta-analysis of the relation between GHb level and the
cardiovascular outcomes due to the weight calculation. Except
that 1 study showed no association [22], the results from the
remaining 7 studies all suggested positive associations between
GHb level and the cardiovascular outcomes with 3 studies
reported significant P values (P,0.05) for testing the linear trend
[23,24].
Only two studies have evaluated the association between the
categories of GHb level and the all-cause mortality and the results
suggested a non-lineal association. One study in United Kingdom
including 47,970 participants identified a ‘‘U-shape’’ association
[18], while another study in the Netherlands including 1,145
participants detected an ‘‘almost positive’’ association [19]. With
the limited numbers of the studies, we could not conduct the dose-
response meta-analysis.
Discussion
The meta-analysis of 26 prospective studies provides evidence
that chronic exposure to increased glycemic level was associated
with increased risks of all-cause mortality and cardiovascular
outcomes in type 2 diabetes. We found that every 1% increase in
GHb was associated with a 15% increase in hazard of all-cause
mortality, 25% in CVD mortality, 17% in CVD, 15% in CHD,
17% in fatal CHD, 11% in heart failure, 11% in stroke, and 29%
in PVD event. From the data of 8 prospective studies with 3 or
more categories of GHb, we found a positive dose-response
association, which provides additional support for our results of
GHb level as a continuous variable and the major outcomes.
Our finding that an increased GHb level is associated with an
increased risk of cardiovascular outcome is consistent with
previous studies. This effect has been shown to be independent
of other vascular risk factors. In a meta-analysis [15], Selvin et al.
evaluated 10 prospective studies and concluded that every 1%
increase in GHb was associated with a 18% increase in hazard of
CVD, 13% in CHD, 16% in fatal CHD, and 17% in stroke
incidence after controlling for potential confounders. These effect
sizes are similar to those estimated in our study for CVD and
CHD but higher for stroke. It may be due to the fewer stroke
events (396) in the previous study. Our estimates from observa-
tional studies are highly consistent with the results from the RCTs.
A meta-analysis of 5 RCTs showed, during 5-year treatment,
reduction of HbA1c by 0.9% resulted in a 17% significant
reduction in non-fatal MI events, 15% in CHD events, but non-
significant reduction in stroke events in type 2 diabetic patients
[12]. Another two meta-analyses of 4 or 5 relevant RCTs reported
similar results, and also found non-significant reduction in HF
events in type 2 diabetics [11,13]. Ray et al. explained that the
cases of stroke event in these RCTs were less than that myocardial
infarction were reported, which may not have enough power to
ascertain whether a significant benefit exists [12]. Due to the lack
of case numbers and the total study sample sizes of each category
of GHb, we could not conduct a dose-response analysis to identify
the relationship between GHb level and the CVD outcomes;
however, a positive association between GHb and CVD incident
was suggested by carefully summarized findings from 8 studies
(Table 2).
The relationship between GHb level and death has been studied,
but the results are inconsistent. A previous meta-analysis of 10
prospective studies [15] did not have available data on all-cause
mortality. Another meta-analysis of RCTs showed no association
between GHb and CVD and all-cause mortality [11–13]. The short
follow-up time, the small number of events, and the glucose-
lowering drugs used in these clinical trials may actually have adverse
cardiovascular effects, which would attenuate macrovascular
benefits of improved glycemic control [59]. In the present study, a
monotonic positive association between GHb level and the risks of
all-cause mortality and CVD mortality was found. Every 1%
increase inGHbwas associated with a 16% increase in hazard of all-
cause mortality, however we cannot assess the dose-response
association between GHb and all-cause mortality due to the small
number of prospective studies with 3 or more categories of GHb
[18,19]. Currie et al [18] found a U-shape association between the
HbA1c level and all-cause mortality: low (6.4%) and high (10.6%)
mean HbA1c values were associated with increased all-cause
mortality as compared to median mean HbA1c values (7.5%) and
this association was independent of the treatment regimen. Land-
man et al [19] detected an almost positive association between the
HbA1c level and the risk of all-cause mortality. The results from
RCTs [11–13] demonstrated that a low HbA1c therapeutic target
level did not result in decreased mortality. The Action to Control
Cardiovascular Risk inDiabetes (ACCORD) trial [60] was halted in
February 2008 because of an unexpected excess of all-cause and
CVD-related mortality in the intensive treatment group, suggesting
that loweredHbA1c concentrationmight cause an excess risk for all-
cause mortality. A clear adverse consequence of tight glycemic
control was a 2 to 3 fold increased risk for severe hypoglycemia.
These studies samples were composed ofmostly elderly subjects with
mean age at least 64 years. Nevertheless, these studies have
important implications for clinical practice [60].
There are several biologically plausible mechanisms that might
account for the finding that chronic hyperglycemia is associatedwith
cardiovascular outcomes and all-cause mortality. Hyperglycemic
periods play a major role in the activation of oxidative stress and
overproduction of mitochondrial superoxide, which trigger various
metabolic pathways of glucose-mediated vascular damage [61,62].
Glucose can react with various proteins to form advanced glycation
end products, which may contribute to long-term complications in
diabetes, plaque formation, and atherosclerosis [59]. These effects
are gradual and likely to be cumulative, occurring during decades of
exposure to chronically elevated blood glucose levels. As explained
by Selvin et al [15], this possibility suggests that most previous
studies, including clinical trials, may have had insufficient follow-up
to detect a moderate increase in risk.
This meta-analysis has notable strengths. We included many
large studies with a correspondingly high number of incident cases,
which improved the statistical power to detect significant
differences. Our study was based on a comprehensive literature
search. We believed that the inclusion of large studies, such as the
10-year post-trial monitoring of the UKPDS [47], and larger
cohort studies conducted by Currie et al [18] in GPRD, Iribarren
et al [21] in Kaiser Permanente Medical care, and Elley et al [24]
in New Zealand, could potentially make our analysis more
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reliable. In addition, our sensitivity analysis showed minimal
influence on the combined results for any single study, and the
heterogeneity of variance between studies was allowed for by using
random effects models. There are several limitations in this review.
First, all studies were observational in nature and residual
confounding cannot be totally ruled out. Second, the analysis
was based on a single measurement of GHb, although GHb is
indicative of time-averaged blood glucose concentration over the
past 3 months [63]. Third, because of the lacking data, the dose-
response relationships between GHb and CVD events and
mortality cannot be estimated in the current analysis. Finally, as
with any other systematic literature review, a limitation is a
potential of publication bias, but the estimates in our study are
similar to previous studies.
In conclusion, our results suggest that chronic hyperglycemia is
associated with increased risks for cardiovascular outcomes and
all-cause mortality among patients with type 2 diabetes and
independent from other conventional risk factors. Our finding
supports the notion that diabetic patients with higher GHb level
should be closely followed due to their higher risks of cardiovas-
cular outcomes and all-cause mortality. In addition, our data
suggest that it might be desirable to achieve GHb as close to the
normal glycemic range as possible.
Supporting Information
Figure S1 Funnel plots with 95% confidence limits for
publication bias. CVD: cadiovascular diseases; CHD: conoary
heart disease; PAD: peripheral arterial disease; RR: relative risk;
SE: standard error.
(TIF)
Table S1 Quality assessments* on prospective cohort
studies on Glycosylated Hemoglobin Level in relation to
Cardiovascular Outcomes and Death in Patients with
Type 2 Diabetes.
(DOC)
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